Acurx Pharmaceuticals’ (NASDAQ: ACXP) earnings release is scheduled for Thursday, March 16, 2023. And like most biotechs, investors will be more focused on what the company says than what it posts. That’s typical. Clinical-stage drug development companies rarely post meaningful revenues. But, they provide guidance and clinical program updates, two areas where investors can appraise what the company is doing and where it’s going. Acurx Pharmaceuticals is expected to present plenty of each, and they could be milestones reached.
First, ACXP is expected to provide an exact number of patients enrolled in its Phase 2b trial. The better news could be that if data in this third set of patients confirms what was demonstrated during the first two-thirds of the study, ACXP could guide toward potential early termination of Phase 2b based on successful data and the urgency to get a better treatment to market. Shares could rally on that news.
Potential For Expedited Review Of Phase 2b Data
Another update could shed additional light on ACXP’s filing with the FDA to get an expedited review of its Phase 2b data. Giving that effort a push is an experienced and expert infectious disease team, which ACXP assembled as its “Independent Data Monitoring Committee” to look at the blinded data at 36 patients enrolled. Remember, an IDMC recommended early terminating its Phase 2a trial based on efficacy. If that is a precedent, ACXP could earn the same benefit, putting them on a direct path to its pivotal Phase 3 trial. Again, worthy of share price appreciation.
Biotech investors like to know if their investments are funded. ACXP is expected to update there as well. Details of the company’s efforts to secure CARB-X funding, including the potential dollars in play, would be welcomed news in ACXP’s mission to get its second antibiotic to the end of Phase 1 clinical trials. A final decision by Carb-X will be in April, which puts another catalyst, this time financial, in the crosshairs. Remember, because the funds are non-dilutive, they could add significantly to ACXP’s cash-per-share valuation. If funding scores over $10 million, it could justify a share price increase of $1.00 on a cash-to-shares consideration.
Updates On Non-Dilutive Funding Opportunities Expected
Other updates could provide insight into additional non-dilutive opportunities, progress in its secondary trials, and an update specific to revenue-generating opportunities in play from its ibezapolstat Phase 2b candidate treating C. difficile. Keep in mind Acurx Pharmaceuticals appears to be distancing itself from potential competitors. To date, Pfizer’s (NYSE: PFE) vaccine candidate PF-06425090, and the antibiotics cadazolid investigated by Johnson & Johnson (NYSE: JNJ) and surotomycin, investigated by Merck & Co (NYSE: MRK), failed to meet their primary endpoints. They are not the only ones falling short of expectations. Last year, Summit Therapeutics (NASDAQ: SMMT) decided to table the development of ridinilazole for pediatric C. diff. And in January of this year, Finch Therapeutics Group (NASDAQ: FNCH) halted its development of a fecal transplant technology for recurrent C. diff after failing to meet its intended objectives.
All told, ACXP may have quite a bit of good news in the queue, and Thursday could be the start of that feed. Stay tuned to its news channel here.
Disclaimers: Hawk Point Media Group, Llc. is responsible for the production and distribution of this content. Hawk Point Media Group, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media Group, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media Group, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media Group, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Hawk Point Media Group, Llc., its authors, contributors, or its agents have not been compensated for preparing research, video graphics, this interview, and/or editorial content contained in this article. Hawk Point Media Media Group Llc. has been compensated by a third-party up to one-thousand—two hubndred-dollars as reimbursement for costs related to content production and nationwide syndication. As such, and because those funds may be construed as compensation, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Company Name: Hawk Point Media
Contact Person: Kenny Ellis
City: Miami Beach
Country: United States